Literature DB >> 19711425

The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers.

Sven Schüngel1, Laura Elisa Buitrago-Molina, Padmavathi devi Nalapareddy, Margitta Lebofsky, Michael P Manns, Hartmut Jaeschke, Atan Gross, Arndt Vogel.   

Abstract

UNLABELLED: The BH3-interacting domain death agonist Bid has been shown to be critical for Fas-induced hepatocellular apoptosis. Furthermore, some studies have suggested that phosphorylation of Bid may determine its apoptotic function and may act as a switch to nonapoptotic functions. The aim of this study was to evaluate the role of Bid and phosphorylated Bid for Fas ligand (FasL)-induced apoptosis in murine livers. The monoclonal antibody Jo2 and a hexameric form of sFasL (MegaFasL) were used to induce apoptosis in wild-type, Bid-deficient (Bid(-/-)), Bid transgenic mice expressing a nonphosphorable form of Bid and Fas receptor-deficient lpr mice. Apoptosis sensitivity was determined in healthy mice and in mice following bile duct ligation, partial hepatectomy, or suramin pretreatment. As previously reported, loss of Bid protects mice against Jo2-induced liver failure. Remarkably however, Bid(-/-) mice are highly sensitive to MegaFasL-induced apoptosis. MegaFasL-treated Bid(-/-) mice showed a typical type I cell signaling behavior with activation of caspase-3 without Bax translocation to the mitochondria and no cytochrome C/Smac release into the cytosol. In contrast to previous in vitro findings, phosphorylation of Bid does not affect the sensitivity of hepatocytes to Fas receptor-mediated apoptosis in vivo.
CONCLUSION: Our data suggest that Bid mainly amplifies a weak death receptor signal in quiescent and nonquiescent hepatocytes rendering the liver more sensitive to FasL-induced apoptosis. Thus, depending on the efficacy of Fas receptor activation, hepatocytes and nonparenchymal cells can either behave as type I or type II cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19711425      PMCID: PMC2905662          DOI: 10.1002/hep.23176

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

Review 1.  CD95-induced apoptosis in human liver disease.

Authors:  P R Galle; P H Krammer
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

2.  Two CD95 (APO-1/Fas) signaling pathways.

Authors:  C Scaffidi; S Fulda; A Srinivasan; C Friesen; F Li; K J Tomaselli; K M Debatin; P H Krammer; M E Peter
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

3.  Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.

Authors:  H Li; H Zhu; C J Xu; J Yuan
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

4.  Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.

Authors:  X Luo; I Budihardjo; H Zou; C Slaughter; X Wang
Journal:  Cell       Date:  1998-08-21       Impact factor: 41.582

5.  Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice.

Authors:  Sören T Eichhorst; Andreas Krueger; Susanne Müerköster; Stefanie C Fas; Alexander Golks; Uwe Gruetzner; Louise Schubert; Christine Opelz; Manfred Bilzer; Alexander L Gerbes; Peter H Krammer
Journal:  Nat Med       Date:  2004-05-16       Impact factor: 53.440

6.  Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death.

Authors:  A Gross; X M Yin; K Wang; M C Wei; J Jockel; C Milliman; H Erdjument-Bromage; P Tempst; S J Korsmeyer
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

7.  Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.

Authors:  Arndt Vogel; Inge E T van Den Berg; Muhsen Al-Dhalimy; John Groopman; Ching-Nan Ou; Olga Ryabinina; Mihail S Iordanov; Milton Finegold; Markus Grompe
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

8.  Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice.

Authors:  V Lacronique; A Mignon; M Fabre; B Viollet; N Rouquet; T Molina; A Porteu; A Henrion; D Bouscary; P Varlet; V Joulin; A Kahn
Journal:  Nat Med       Date:  1996-01       Impact factor: 53.440

9.  Fas ligand in human serum.

Authors:  M Tanaka; T Suda; K Haze; N Nakamura; K Sato; F Kimura; K Motoyoshi; M Mizuki; S Tagawa; S Ohga; K Hatake; A H Drummond; S Nagata
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

10.  Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity.

Authors:  P Schneider; N Holler; J L Bodmer; M Hahne; K Frei; A Fontana; J Tschopp
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

View more
  15 in total

Review 1.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

Review 2.  Fas death receptor signalling: roles of Bid and XIAP.

Authors:  T Kaufmann; A Strasser; P J Jost
Journal:  Cell Death Differ       Date:  2011-09-30       Impact factor: 15.828

3.  Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice.

Authors:  Milos Lazic; Akiko Eguchi; Michael P Berk; Davide Povero; Bettina Papouchado; Anny Mulya; Casey D Johnson; Ariel E Feldstein
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

4.  Caspase inhibitors for the treatment of liver disease: friend or foe?

Authors:  Benjamin L Woolbright; Wen-Xing Ding; Hartmut Jaeschke
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-03-04       Impact factor: 3.869

Review 5.  The role of apoptosis in acetaminophen hepatotoxicity.

Authors:  Hartmut Jaeschke; Luqi Duan; Jephte Y Akakpo; Anwar Farhood; Anup Ramachandran
Journal:  Food Chem Toxicol       Date:  2018-06-18       Impact factor: 6.023

6.  PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo.

Authors:  Rong-Hua Tao; Zuzana Berkova; Jillian F Wise; Abdol-Hossein Rezaeian; Urszula Daniluk; Xue Ao; David H Hawke; Judith E Karp; Hui-Kuan Lin; Jeffrey J Molldrem; Felipe Samaniego
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

Review 7.  Rejuvenating Bi(d)ology.

Authors:  S S Zinkel; X M Yin; A Gross
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

Review 8.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

9.  Balance between short and long isoforms of cFLIP regulates Fas-mediated apoptosis in vivo.

Authors:  Daniel R Ram; Vladimir Ilyukha; Tatyana Volkova; Anton Buzdin; Albert Tai; Irina Smirnova; Alexander Poltorak
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-21       Impact factor: 11.205

Review 10.  Xenobiotic and Endobiotic Mediated Interactions Between the Cytochrome P450 System and the Inflammatory Response in the Liver.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Adv Pharmacol       Date:  2015-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.